• MCI Onehealth (DRDR) and Palantir Technologies signed a three-year commercial agreement to power MCI’s clinical insights
  • Palantir’s Foundry platform will power analytics for improved MCI patient care and research projects for MCI’s international stakeholders
  • Through Palantir, MCI and relevant health stakeholders can securely identify and offer new treatment and clinical trial opportunities
  • MCI is a healthcare technology company focused on improving primary care
  • MCI Onehealth Technologies Inc. (DRDR) is up 2.40 per cent, trading at C$1.28 per share at 4:15 pm ET

MCI Onehealth (DRDR) and Palantir Technologies signed a three-year commercial agreement to power MCI’s clinical insights.

Palantir’s Foundry platform will power analytics for improved MCI patient care and research projects for MCI’s international stakeholders in the health, pharma, therapeutic, and life sciences sectors. The partnership with Palantir supports and helps accelerate MCI’s partnerships with other health innovators like MDClone.

Dr. Alexander Dobranowski, MD, Chief Executive Officer of MCI, commented on the news.

“We’re using data to screen patients – rapidly and proactively – for chronic and rare diseases, for clinical trials, and matching patients to see appropriate specialists within and outside the MCI network for appointments within four weeks. Doing this with Palantir, not only drives our mission forward, but also ensures that regard for our patients is always front-and-centre”.

MCI’s collaboration with Palantir will continue to accelerate MCI’s data strategy in disease screening, novel referral optimization and other custom data and precision medicine initiatives. Health researchers can access MCI-generated insights to understand disease progression better. It enhances care delivery and develops new products and treatments. This can improve patient outcomes – which can help reduce overall health system costs.

Palantir Foundry’s embedded data protection capabilities, including granular access controls, end-to-end provenance, and audit, ensures MCI can secure sensitive health data while enabling access to only authorized users for approved purposes. Through Palantir, MCI and relevant health stakeholders can securely identify and offer new treatment and clinical trial opportunities. 

MCI is a healthcare technology company focused on improving primary care. It empowers patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs.

MCI Onehealth Technologies Inc. (DRDR) is up 2.40 per cent, trading at C$1.28 per share at 4:15 pm ET.


More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.